Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Incyte

Geron poleaxed as partner J&J abandons only pipeline drug

Geron poleaxed as partner J&J abandons only pipeline drug Analysts have suggested that might be a tough call given the increasingly competitive markets for MF and MDS, with firmly entrenched therapies such as Incyte and Novartis’ Jakafi (ruxolitinib) and

J&J files ‘breakthrough’ bladder cancer drug in US

J&J files ‘breakthrough’ bladder cancer drug in US J&J could face near-term competition in the oral FGFR inhibitor category from Incyte, whose pemigatinib candidate is in phase 2 testing for bladder cancer and myeloid/lymphoid cancers, and ... Data from mid-stage studies should be available next year,

Cancer immunotherapy: What's on the horizon?

Cancer immunotherapy: What's on the horizon? article – but, as recent experience with Incyte and Nektar Therapeutics has shown, not all new drugs and combinations will succeed. ... Meanwhile, Incyte’s Merck &Co partnered IDO inhibitor epacadostat bombed when paired with Keytruda in a melanoma

GSK sells eczema and psoriasis drug to Dermavant for £250m

GSK sells eczema and psoriasis drug to Dermavant for £250m s Xeljanz (tofacitinib) and Incyte/Eli Lilly’s Olumiant (baricitinib).

CTI slumps as Servier-partnered lymphoma drug fails

CTI slumps as Servier-partnered lymphoma drug fails If approved, it will compete with Incyte and Novartis' Jakafi (ruxolitinib) in myelofibrosis, which is predicted to knock on the door of $1.5bn in sales this year on the back

[ Previous 5 results ] 3 4 5 6 7 8 9 10 11 12 [ Next 5 results ]

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Report: Reinventing product and portfolio value for the biopharmaceutical industry
Gain practical advice on determining and communicating product and portfolio value, including why, in fast-paced and evolving markets, you need to consider the evidence requirements of a growing network of...
Neil Thompson
How AI is finally helping rare diseases gain more than just attention
By Neil Thompson...
Is communication failing us?
Compelling people to care in a world oversaturated with news and information...